This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Julia A. McMillan, MD; Frank A. Oski, MD

JAMA. 1991;265(23):3156-3158.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

As is so often the case in pediatrics, prevention, especially the use of vaccines, proved to be one of the major areas of attention during the past year. Other major developments included reports of a role for vitamin A for the possible prevention of millions of childhood deaths worldwide and the demonstration of a method for producing a more optimistic developmental outcome for the low-birth-weight infant.

In October 1990 a diphtheria protein—conjugated Haemophilus influenzae type b vaccine (HibTITER, Praxis Biologics Inc, Rochester, NY) was licensed for use in infants beginning at 2 months of age.¹Haemophilus influenzae type b is the most frequent cause of invasive bacterial infection among children between the ages of 1 month and 3 years. Immunologic immaturity of infants and young children has made vaccine prevention for this most susceptible age group impossible in the past. Capsular polysaccharide vaccine (PRP) was licensed in the United . . . [Full Text PDF of this Article]

Author Affiliations
The Johns Hopkins University School of Medicine, Baltimore, Md

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?